Aclarubicin (6 mg/m²) will be administered intravenously through a central venous access device over 1 hour for four consecutive days (Days 2-5) of each 28 day cycle to each participant [Retinal Vasculopathy with Cerebral Leukodystrophy (RVCL) patients]. There is no maximum number of cycles.

Vasculopathy, Retinal, With Cerebral Leukodystrophy

Cerebroretinal Vasculopathy, Hereditary

Aclarubicin (3 mg/m²) will be administered intravenously through a central venous access device over 1 hour for four consecutive days per 28 day cycle. There is no maximum number of cycles.

aclarubicin

Washington University School of Medicine

Aclarubicin for the Treatment of Retinal Vasculopathy With Cerebral Leukodystrophy

A Pilot Study of Aclarubicin for the Treatment of Retinal Vasculopathy With Cerebral Leukodystrophy (RVCL)

Volume increase in lesions on FLAIR MRI between baseline and six months is assessed

dolichol/povraćanje

Aclarubicin for the Treatment of Retinal Vasculopathy With Cerebral Leukodystrophy

Najkompletnija baza ljekovitog bilja potpomognuta znanošću